Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background In order to counteract fatigue, physical activity (PA) is recommended for all stages of cancer. However, only few advanced cancer patients (ACP) are physically active. Quantitative data with high numbers of ACP reporting barriers to PA are missing. This study aimed to identify barriers to PA in ACP with tiredness/weakness and investigate their motivation towards it.
Background: Combination chemotherapy plus anti-EGFR (epidermal growth factor receptor) antibody is approved for first-line therapy in metastatic colorectal cancer in patients with RAS wild type tumors. The combination of FOLFOX with panitumumab has led to significantly better outcome when compared to chemotherapy alone. The cumulative oxaliplatin toxicity resulting in dose limiting neurotoxicity has led to the development of maintenance strategies.
Background: The multicenter, single-arm, phase II trial (Simon's two stage design) evaluated the efficacy of mFOLFOX6 + cetuximab (500 mg/m2) q2w as 1st line therapy in KRAS wt mCRC. Final extended molecular and subgroup analyses are presented. Methods: Primary endpoint was response rate (ORR) per RECIST 1.0. In stage 1 and 2, 13 and 25 responders were needed in 37 and 53 pts, respectively, to further evaluate this therapy (H p > 0.55).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
